NKILT Therapeutics
PrivateLast Round
Accelerator
Sep 19, 2022
Momentum
Top 25%
of companies Caplight tracks
Company Overview
NKILT Therapeutics is a biotechnology company developing allogeneic, off-the-shelf natural killer (NK) cell therapies for the treatment of leukemias and solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NKILT Therapeutics Comparables
Compare NKILT Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shoreline Biosciences | 86% | |
| Invectys | 81% | |
| Indapta Therapeutics | 79% | |
NKILT Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Sep 19, 2022 |
Key People
Founding team and executive leadership
NKILT Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Innovation Space | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 17, 2026
Monthly visitors grew 197% MoM, reaching 2K.
NKILT Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about NKILT Therapeutics's valuation, stock price, and market status.